1. Introduction {#sec1}
===============

A randomized, controlled clinical trial with concurrent control arm is the optimal way to minimize bias when evaluating the effect of an experimental intervention. Sometimes it is infeasible or unethical to carry out a randomized study, and a single-arm trial is conducted. In addition, there is growing interest in studies designed to de-escalate therapy to reduce morbidities such as adverse effects, inconvenience and costs of standard-of-care treatments \[[@bib1]\]. Although randomized non-inferiority studies can be conducted, these require large sample sizes, are costly to conduct, are of little interest to highly resourced funders, and are often difficult to interpret due to the arbitrary nature of the non-inferiority margin. Thus, single-arm de-escalation studies are appealing.

One setting for de-escalation, where randomization is not ethical, is to determine whether temporary interruption of adjuvant endocrine therapy for young breast cancer patients who wish to become pregnant is safe \[[@bib2], [@bib3], [@bib4]\]. POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer; NCT02308085) is a prospective, single-arm, international study designed to evaluate pregnancy outcomes and safety of temporarily interrupting endocrine therapy for young women with estrogen receptor positive (ER+) breast cancer who desire pregnancy. The interim and final analyses are based on assumptions regarding historical control rates of breast cancer events, and the protocol prospectively planned to reassess these assumptions. POSITIVE is led by the International Breast Cancer Study Group (IBCSG), with global participation from the Breast International Group (BIG), and United States National Clinical Trials Network (US NCTN) coordinated by the Alliance for Clinical Trials in Oncology.

In order to place the results of the POSITIVE study into context, we describe two methods that rely only on baseline characteristics of participants to estimate standard-of-care external control breast cancer event rates for the single-arm POSITIVE trial. To facilitate the Data and Safety Monitoring Committee review scheduled for November 2018, 272 POSITIVE participants enrolled prior to August 1, 2018 were included. We use outcome data for patients in the SOFT and TEXT clinical trials \[[@bib5], [@bib6], [@bib7], [@bib8]\] who did not interrupt their adjuvant endocrine therapy.

2. Materials and methods {#sec2}
========================

2.1. POSITIVE trial {#sec2.1}
-------------------

Women between 18 and 42 years of age who desired to become pregnant and had completed 18--30 months of adjuvant endocrine therapy for early-stage ER + breast cancer were eligible to enroll in POSITIVE. An interruption of endocrine therapy for up to 2 years is permitted to allow pregnancy attempt (after a 3-month washout period), delivery, and breastfeeding. Resumption of endocrine therapy to complete 5--10 years of treatment is expected as soon as pregnancy and breastfeeding are finished, or after it is determined that conception is not possible. The accrual goal was 500 patients.

The primary objective is to assess the risk of breast cancer recurrence associated with temporary interruption of endocrine therapy to permit pregnancy. The primary analysis will estimate breast cancer free interval (BCFI), defined as the time from enrollment in the study to the first invasive breast cancer event (local, regional, or distant recurrence or a new invasive contralateral breast cancer), and estimated by Kaplan-Meier method with focus on the 3-year event percentage. The protocol includes three interim monitoring time points to permit early stopping of the trial in case the observed risk of a breast cancer event is higher than anticipated, based on historical control estimates. The primary analysis is planned based on 1600 patient-years of follow-up (approximately 3 years median follow-up).

2.2. SOFT/TEXT trials {#sec2.2}
---------------------

Prior to launching POSITIVE, data from the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT) \[[@bib5], [@bib6], [@bib7], [@bib8]\] were used to estimate the historical control risk of a breast cancer event if adjuvant endocrine therapy had not been interrupted. Based on the entire cohort of 5738 premenopausal women enrolled in SOFT/TEXT between 2003 and 2011, the estimated 3-year BCFI percent was 94.2%, corresponding to a 5.8% 3-year BCFI event percent (2% annual risk of a breast cancer event). This anticipated rate was used to design the interim monitoring plans and primary analysis for the POSITIVE trial. The POSITIVE protocol prespecified that, prior to reporting trial results, SOFT/TEXT data would be used to re-estimate the external control 3-year BCFI event percent based upon characteristics of patients actually enrolled in POSITIVE. Such re-estimation is the subject of this report.

SOFT and TEXT are two international Phase III randomized clinical trials in premenopausal patients with ER + breast cancer led by the IBCSG. In SOFT, patients were randomized to receive either tamoxifen alone, or ovarian function suppression (OFS) with tamoxifen, or OFS with the aromatase inhibitor (AI) exemestane, after completion of adjuvant chemotherapy or following surgery alone. In TEXT, patients were randomized to receive OFS with exemestane or OFS with tamoxifen, after surgery and before starting any adjuvant therapy.

Estimating Historical Control using SOFT/TEXT patients.

First, we identified a cohort of SOFT/TEXT patients with POSITIVE criteria eligibility ("eligible SOFT/TEXT cohort"). Because the median duration of adjuvant endocrine therapy received by the POSITIVE participants prior to their enrollment in the study was 24 months, we identified SOFT/TEXT patients who received at least 24 months of adjuvant endocrine therapy, and were 18--42 years old and still disease-free (no invasive breast cancer recurrence, contralateral breast cancer, or second non-breast malignancy) when they reached 24 months of therapy. Patients who had undergone oophorectomy or hysterectomy by 24 months of endocrine therapy were excluded. Patients with more than 10 positive lymph nodes were excluded to reflect the cancer characteristics of POSITIVE participants. As allowed by the protocol, some SOFT patients had initiated oral endocrine therapy prior to study enrollment, and this was taken into account in assessing eligibility.

Two methods, described below, were used to estimate historical control based on the eligible SOFT/TEXT cohort:

[Method I]{.ul}: *Direct estimate based on the SOFT/TEXT cohort eligible for POSITIVE.* The annualized hazard rate of BCFI event over the first three years since eligibility was calculated using the maximum likelihood estimates from an exponential model. This estimate (reported as percent) is the number of BCFI events occurring within the first three years divided by the total years of follow-up accrued by patients at risk during that interval. The 3-year BCFI event rate was estimated based by Kaplan-Meier method.

[Method II]{.ul}: *Estimate based on the SOFT/TEXT cohort group-matched to enrolled POSITIVE participants.* First, we examined the distribution of patient, disease and treatment characteristics of POSITIVE and eligible SOFT/TEXT cohorts and identified those characteristics that differed ([Table 1](#tbl1){ref-type="table"}). The associations of each of these characteristics with BCFI over the 0- to 3-year interval were further examined in the SOFT/TEXT cohort by fitting univariate Cox models ([Table 2](#tbl2){ref-type="table"}), and if the factor was unbalanced (i.e., p \< 0.20 in the univariate Cox model), then the characteristic was selected for matching. The five identified matching factors were used to divide the POSITIVE participants and the SOFT/TEXT cohort into 72 strata. Factors included age (\<35, 35--39, 40--42 years), body mass index (BMI) (unknown/normal, overweight/obese), nodal status (pN0, pN+1--3, pN+4--9), prior AI received (yes, no), and prior chemotherapy received (yes, no). Of note, in some instances the number of patients in a stratum was 0. The SOFT/TEXT cohort was sampled with replacement so that the number of patients allocated to each stratum in the SOFT/TEXT cohort was proportional to the number of participants in the corresponding stratum in POSITIVE. If the matched stratum was empty, then a SOFT/TEXT patient from the stratum nearby was chosen. The random sampling of the SOFT/TEXT cohort was repeated 5000 times. For each sample, the annualized hazard rate of a BCFI event and 3-year BCFI event rate were calculated. The annualized hazard rate of BCFI event was calculated using the maximum likelihood estimate from a piecewise exponential model (for intervals 0--3 years and \>3 years) and the 3-year BCFI event rate was calculated based on Kaplan-Meier method. The estimates of the true annualized hazard rate for BCFI and the true 3-year BCFI event rate were calculated by taking the mean of the 5000 estimates. Non-parametric 95% confidence intervals were derived using the 2.5th and 97.5th percentiles of the distribution of the 5000 estimates for each respective parameter.Table 1The distribution of patient, treatment and disease characteristics for the POSITIVE participants (N = 272), the eligible SOFT/TEXT cohort (N = 1499), and the means of the 5000 random sample sets drawn from the eligible SOFT/TEXT cohort using Method II.Table 1POSITIVE enrolled (N = 272)SOFT/TEXT eligible (N = 1499)SOFT/TEXT group matched random samples[a](#tbl1fna){ref-type="table-fn"}N%N%%Age (years)\<359233.828619.133.935-3911040.457338.240.340-427025.764042.725.8Body mass index (BMI; kg/m^2^)Normal (\<25)19973.287158.172.9Overweight (25-\<30)4315.833722.513.2Obese (≥30)217.725717.110.5Unknown93.3342.33.4Previous pregnancyNo16058.838725.833.0Yes11241.2111274.267.0Previous delivery of a babyNo20073.543128.835.7Yes7226.5106871.264.3No. nodes positivepN018266.979453.066.6pN+ 1--37527.652334.928.1pN+ 4--9145.117511.75.3Unknown10.470.5Tumor size (path.; cm)≤2 cm16962.184756.563.5\>2 cm9735.760540.433.6Unknown62.2473.13.0Tumor grade14717.322314.917.3212746.777051.452.539133.547831.928.9Unknown72.6281.91.3HER2 statusNegative20876.5119179.577.7Positive6122.425617.117.6Unknown31.1523.54.7Estrogen receptor (ER ≥ 10%)Negative31.1422.82.1Positive26998.9145797.297.9Progesterone receptor (PgR≥10%)Negative3011.018112.111.1Positive23987.9130086.787.8Missing31.1181.21.1Prior chemotherapyNo10538.635923.937.5Yes16761.4114076.162.5Prior AI receivedNo21478.789359.678.5Yes5821.360640.421.5Prior OFS receivedNo12144.531521.023.4Yes15155.5118479.076.6[^3]Table 2The estimates of 3-year BCFI rates in the eligible SOFT/TEXT cohort (N = 1499) according to unbalanced characteristics (p-values from univariate Cox models[a](#tbl2fna){ref-type="table-fn"}).Table 23-year BCFIP-value%Age (years)\<3587.70.1235-3990.640-4291.8Body mass index (BMI; kg/m^2^)Normal (\<25)91.20.17Overweight (25-\<30)87.6Obese (≥30)91.8Previous delivery of a babyNo90.30.81Yes90.6No. nodes positivepN093.4\<.0001pN+ 1--389.1pN+ 4--982.1Prior chemotherapyNo95.00.003Yes89.2Prior AI receivedNo88.40.002Yes93.7Prior OFS receivedNo89.40.40Yes90.9[^4]

3. Results {#sec3}
==========

Of 5738 SOFT/TEXT patients, 1499 met the eligibility criteria for POSITIVE. [Table 1](#tbl1){ref-type="table"} shows that the patients enrolled in POSITIVE are younger, less overweight/obese, and had fewer positive lymph nodes than the eligible SOFT/TEXT cohort. Also, as expected, fewer POSITIVE patients had prior delivery/pregnancy and fewer POSITIVE patients received prior AI, chemotherapy and OFS.

[Table 2](#tbl2){ref-type="table"} summarizes 3-year BCFI event percentages and the p-values from the univariate Cox models for the unbalanced factors identified in [Table 1](#tbl1){ref-type="table"}. As prior pregnancy is highly correlated with prior delivery, only prior delivery was examined in [Table 2](#tbl2){ref-type="table"}. The factors associated with BCFI (with p-value \<0.2) are age, BMI, nodal status, whether prior AI was received and whether prior chemotherapy was received. Those factors were used for matching in Method II. The right-hand column in [Table 1](#tbl1){ref-type="table"} summarizes the means of the distributions of the characteristics over the 5000 random sample sets generated from Method II. After matching, as expected, the distributions of the matched characteristics are indeed very similar to those of POSITIVE. Although some unmatched characteristics remain unbalanced, they are both closer to the distribution in POSITIVE and have little influence on BCFI outcome.

[Table 3](#tbl3){ref-type="table"} gives the results obtained from Methods I and II for BCFI. In Method I, based on the eligible SOFT/TEXT cohort with 1499 patients, the annualized hazard rate of BCFI during the first three years is 3.4% per year with 95% CI (2.8%, 4.0%). The 3-year BCFI event rate is 9.5% with 95% CI (7.9%, 11.1%).Table 3BCFI estimates∗ from Methods I and II.Table 3Annualized hazard rate over the first 3 years95% CI3-year BCFI event rate95% CIRate assumed in the original POSITIVE design2%5.8%Method I3.4%(2.8%, 4.0%)9.5%(7.9%, 11.1%)Method II[a](#tbl3fna){ref-type="table-fn"}3.4%(2.8%, 4.0%)9.4%(7.8%, 10.9%)[^5][^6]

Using Method II, based on the 5000 random sample sets to group-match SOFT/TEXT to POSITIVE patients enrolled, the mean of the annualized risk is 3.4% (95% CI, 2.8%, 4.0%). The mean of 3-year BCFI event rates is 9.4% (95% CI, 7.8%, 10.9%). [Fig. 1](#fig1){ref-type="fig"} shows the Kaplan-Meier curve of the eligible SOFT/TEXT cohort (Method I), and the averages of the Kaplan-Meier estimates from the 5000 random sample sets (Method II). The two curves are very consistent, supporting the finding that the unmatched and group-matched methods give the same result for this analysis.Fig. 1Kaplan-Meier curves of BCFI for the identified SOFT/TEXT cohort (N = 1499; Method I; 3-year event rate: 9.5%) and the average of 5000 random samples (Method II; 3-year event rate: 9.4%).Fig. 1

To visually assess the extent to which the 3-year BCFI estimate is influenced by the selection of covariates used for matching, [Table 4](#tbl4){ref-type="table"} shows results of Method II when covariates used for matching are removed one at a time. The 3-year BCFI estimates range from 8.4% to 10.0%. We note that all these estimates based on SOFT/TEXT are greater than the 5.8% assumed for the design of the POSITIVE trial, and all of the 95% confidence intervals based on the models exclude 5.8%.Table 4BCFI estimates from Method II eliminating one factor at a time from the Final Model[a](#tbl4fna){ref-type="table-fn"}.Table 4Annualized hazard rate over the first 3 years95% CI3-year BCFI event rate95% CIRate assumed in the original POSITIVE design2.0%5.8%Method I3.4%(2.8%, 4.0%)9.5%(7.9%, 11.1%)Method II: Final Model[a](#tbl4fna){ref-type="table-fn"}3.4%(2.8%, 4.0%)9.4%(7.8%, 10.9%)Method II: eliminating age3.2%(2.6%, 3.8%)8.9%(7.4%, 10.5%)Method II: eliminating BMI3.4%(2.9%, 4.0%)9.5%(8.0%, 11.1%)Method II: eliminating nodal status3.6%(3.0%, 4.2%)10.0%(8.4%, 11.6%)Method II: eliminating prior AI3.0%(2.4%, 3.6%)8.4%(6.9%, 9.9%)Method II: eliminating prior chemotherapy3.5%(2.9%, 4.1%)9.7%(8.2%, 11.3%)[^7]

4. Discussion {#sec4}
=============

Although randomized clinical trials are the best methodology for comparing two treatment strategies, in some cases they are unethical or infeasible. In designing the POSITIVE trial, it was not reasonable to randomize women with early breast cancer who desire pregnancy to an arm that would not permit pregnancy attempt. In addition, randomized trials designed to demonstrate non-inferiority of a de-escalated therapy versus standard therapy require substantial numbers of patients, often making them infeasible \[[@bib9]\]. Recent single-arm designs assessing de-escalation of therapy, including the APT trial \[[@bib15]\] and the low-risk cohorts of the TAILORx and MINDACT trials \[[@bib16],[@bib17]\], have made this an appealing and clinically valuable design option. However, these single-arm studies are often developed and conducted without pre-specifying historical control datasets that can be used to place the eventual results into clinical context. While estimating "standard-of-care" therapy outcomes for the eligible patient population might be available, estimating historical control outcomes for the cohort of patients actually enrolled is essential to assess the viability of a de-escalation strategy. The methods described in this paper achieve this clinically relevant objective.

Two methods were discussed that estimated the rates of historical controls, using the POSITIVE single-arm breast cancer trial as an example. A cohort of patients from SOFT/TEXT who met POSITIVE eligibility criteria was identified. Method I estimated breast cancer recurrence rates directly using the eligible SOFT/TEXT cohort, while Method II used stratified matching of factors shown to be prognostic. For both methods, only characteristics known at entry into the POSITIVE study were used to estimate the BCFI rates of historical controls. Therefore, in addition to the final analysis and interpretation of definitive results, the described methods have a role for better monitoring event rates during the conduct of the study.

At the later stage of the POSITIVE trial when longer follow-up is available, a traditional Cox proportional hazards modeling or propensity-score Cox proportional hazards modeling \[[@bib10]\] controlling for important risk factors, could be performed based on the eligible SOFT/TEXT cohort and POSITIVE patients to examine the trial effect. As the eligible SOFT/TEXT cohort was selected based on eligibility criteria for the POSITIVE trial, the trial effect could be viewed as mainly due to temporarily interrupting endocrine therapy plus any effect, adverse or favorable, of pregnancy.

Other methods can be explored for evaluating the treatment effect in single-arm trials. The use of synthetic control arm was suggested for a single-arm trial where the data from Medidata's archive of 340 patients with acute myeloid leukemia were mined and matched with the 16 patients from an experimental arm for analysis \[[@bib11]\]. Patients were matched on ≥4 of 6 baseline criteria at the individual patient level and then combined to estimate the treatment effect, as well as for other exploratory subgroup analyses. A control arm can also be constructed from historical data by pair-matching the control patient with each patient on the experimental arm via propensity scores \[[@bib12],[@bib13]\]. Recently, Ventz et al. \[[@bib14]\] examined designs with stringent futility early-stopping rules and those that leverage both toxicity and efficacy endpoints, demonstrating that such designs have little impact on power, but enhanced safety.

The results presented in this paper using Methods I and II were based on one historical dataset (SOFT/TEXT) and 272 POSITIVE patients. To assess robustness of historical controls, these methods should be applied using data from multiple sources. In fact, the POSITIVE protocol specifies that the Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 12 \[[@bib18]\] and ASCO's CancerLinQ may be candidate datasets.

The annualized hazard rate of BCFI event during the first 3 years and the 3-year BCFI event rate obtained from both Methods I and II were higher than those assumed in the POSITIVE protocol ([Table 3](#tbl3){ref-type="table"}). It is reassuring that estimates obtained by the two methods are so similar. These findings are very important for safety monitoring of the POSITIVE trial by the Data and Safety Monitoring Committee, as adjustments to interim monitoring boundaries are appropriate. External control datasets should be identified before launching single-arm, de-escalation trials. Methods, such as those described in this paper, should be applied to provide context for interim monitoring and clinical interpretation of the final results.
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[^4]: In the Cox models, BCFI was censored at 3 years; the p-values reported are from the univariate Cox model with only the characteristic of interest included.

[^5]: ∗There were 168 BCFI events in SOFT/TEXT eligible cohort; among them, 126 occurred within 3 years after time 0.

[^6]: In Method II, 5000 random sample sets of SOFT/TEXT patients were drawn with replacement matching the characteristics of the POSITIVE participants. The matched characteristics used are age (\<35, 35--39, 40--42), BMI (unknown/normal, overweight/obese), nodal status (pN0, pN+1--3, pN+4--9), prior AI received (yes, no), and prior chemotherapy received (yes, no).

[^7]: In the final model, the matched characteristics used are age (\<35, 35--39, 40--42), BMI (unknown/normal, overweight/obese), nodal status (pN0, pN+1--3, pN+4--9), prior AI received (yes, no), and prior chemotherapy received (yes, no).
